Gold and silver prices increased as U.S. Treasury yields fell from multi-decade highs and the U.S. dollar weakened, allowing metals to extend gains after recent payroll data showed slower job growth. Equities in North America and Europe also rose, supported by optimism around AI earnings and easing bond yields. Despite inflation concerns and geopolitical risks in the Middle East affecting oil prices, the market remains cautiously optimistic. Upcoming U.S. economic data, including Fed minutes and jobless claims, will be key to determining the next moves for gold and broader markets.
Metals rise as oil steadies and yields pull back from 24-year highs, with 86 of 150 US stocks on Pluang rising today. For readers following this market snapshot as of Oct 07, 2026 03:02 WIB: FuelCell Energy Inc (FCEL) gained 14.47% to USD 20.68 with a typical hold time of 48 days and 94% sell order activity. Novavax Inc (NVAX) dropped 9.95% to USD 11.31, with 71% buy order activity and a typical hold time of 59 days. Moderna, Inc. (MRNA) fell 7.65% to USD 187.67, with 76% buy order activity and a typical hold time of 59 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
